Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome - Top-Institutions - MDSpire

Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome

  • By

  • Nour Eldeen Mahmoud Shabaan Ibrahim

  • Mohamed Tarek Mounir Zaki

  • Khaled Ahmed Fouad Abdel Magid

  • Khaled Ahmed Fouad

  • Mina Magued Abdalla Iskandar

  • March 27, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Cardiology
    • Interventional Cardiology
    • Diabetes and Metabolic Diseases

  • #2

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Cardiology
    • Interventional Cardiology
    • Endocrinology

  • #3

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Cardiology
    • Interventional Cardiology
    • Diabetes Care

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Interventional Cardiology
    • Endocrinology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Cardiology
    • Interventional Cardiology
    • Diabetes and Metabolism

Original Source(s)

Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome

  • by Nour Eldeen Mahmoud Shabaan Ibrahim, Mohamed Tarek Mounir Zaki, Khaled Ahmed Fouad Abdel Magid, Khaled Ahmed Fouad, Mina Magued Abdalla Iskandar

  • March 27, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

In-stent Carlino—a novel bailout for device-uncrossable in-stent chronic total occlusions

Influence of nursing cardiac rehabilitation on cardiac function and quality of life in patients with coronary heart disease after percutaneous coronary intervention